Buy, Sell or Hold? Analysts Weigh in on Antero Resources Corporation (NYSE:AR), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

In the most recent session, Antero Resources Corporation (NYSE:AR) shares have traded +0.59%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $1.10 away from the 50-day moving average of $19.50 and $-0.72 away from the 200-day moving average of $21.32. From a different angle, the stock has been recently recorded -27.21% off of the 52-week high of 28.30 and +13.00% removed from the 52-week low of 18.23. 

Currently, Antero Resources Corporation has a price to earnings ratio of 479.07. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 3.41.

Price Target Update

Analysts polled by Thomson Reuters have set a consensus target price of $27.34 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.

According to data provided by Zacks Research, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has a consensus target price of $N/A on the stock. Out of the polled analysts providing targets, the high is currently $N/A, while the low is resting at $N/A. Analyst price targets may vary depending on the individual method used to calculate the estimate.
Turning to earnings, analysts are expecting Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to post a current quarter EPS of $N/A. This consensus number is compiled by Zacks Research. For the period ending on N/A, the company reported EPS for the quarter of $N/A. The resulting surprise factor from the difference between the reported number and the consensus estimate going into earnings was N/A%. After a company reports earnings, the stock may see increased activity. The next earnings report date is scheduled on or near N/A.
In terms of analyst ratings, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has a current ABR of N/A. This average broker recommendation is given by Zacks using a scale from 1 to 5. According to this scale, a rating of 1 or 2 would indicate a Buy, and a rating of 4 or 5 would signify a Sell recommendation. A 3 would indicate a Hold on the stock.

Leave a Comment